A Phase III Randomized, Open- Label Multi-center Study of Nilotinib Versus Imatinib in Adult Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Cytogenetic Response (CyR) on Imatinib.
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2015
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ENEST
- Sponsors Novartis
- 03 Jul 2012 Planned number of patients changed from 586 to 608 and additional trial locations added as reported by European Clinical Trials Database record.
- 30 Oct 2009 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 18 Jul 2008 Status changed from recruiting to completed, from clinicaltrials.gov record.